{
  "identity": {
    "bacteriumName": "Serratia marcescens",
    "aliases": [
      "Serratia sp."
    ],
    "lastUpdated": "2025-01-08",
    "clsiCategory": "Enterobacterales (excluding Salmonella/Shigella)",
    "classification": {
      "gramStain": "Gram-negative",
      "morphology": "Bacilli",
      "respiration": "Facultative anaerobe",
      "notes": [
        "Motile",
        "May produce a characteristic red pigment (prodigiosin), especially at room temperature."
      ]
    },
    "strainDetails": [],
    "biochemicalTests": "Gram-negative rod, motile, lactose – (or slow), ONPG +, oxidase –, catalase +, citrate +, VP +, DNase +, gelatinase +, lysine +, ornithine +, esculin +, urease variable, may produce red pigment (prodigiosin) at room temperature."
  },
  "clinicalProfile": {
    "summary": "Serratia marcescens is an opportunistic pathogen that causes a variety of nosocomial and healthcare-associated infections, including urinary tract infections, pneumonia, bloodstream infections, and surgical site infections. Both immunocompetent and immunocompromised individuals can be affected. The increasing prevalence of multi-drug resistant (MDR) strains poses a significant therapeutic challenge.",
    "pathophysiologyPearls": [
      "Produces several virulence factors including proteases, lipases, and DNase, which contribute to tissue damage.",
      "The red pigment, prodigiosin, has immunosuppressive and cytotoxic properties.",
      "Forms biofilms on medical devices, contributing to catheter-related infections and antibiotic resistance."
    ],
    "keySignsAndSymptoms": [
      "Fever, chills, and leukocytosis in cases of bacteremia.",
      "Dysuria, frequency, and urgency in urinary tract infections.",
      "Cough, dyspnea, and purulent sputum in pneumonia.",
      "Erythema, purulent discharge, and pain at surgical or wound sites."
    ],
    "clinicalSyndromes": [
      {
        "syndromeName": "Catheter-Associated Urinary Tract Infection (CAUTI)",
        "description": "One of the most common infections caused by S. marcescens, often associated with indwelling urinary catheters."
      },
      {
        "syndromeName": "Ventilator-Associated Pneumonia (VAP)",
        "description": "A significant cause of nosocomial pneumonia in intubated patients in intensive care units."
      },
      {
        "syndromeName": "Catheter-Related Bloodstream Infection (CRBSI)",
        "description": "Often linked to central venous catheters, particularly in patients receiving parenteral nutrition."
      },
      {
        "syndromeName": "Surgical Site Infection (SSI)",
        "description": "Can contaminate surgical wounds, leading to postoperative infections."
      },
      {
        "syndromeName": "Neonatal Sepsis and Meningitis",
        "description": "Causes outbreaks in neonatal intensive care units (NICUs), leading to severe systemic infections."
      }
    ],
    "stagesOfIllness": [],
    "highRiskPopulations": [
      "Hospitalized patients, especially in intensive care units (ICUs)",
      "Neonates",
      "Immunocompromised individuals",
      "Patients with indwelling medical devices (e.g., catheters, ventilators)",
      "Intravenous drug users"
    ],
    "transmissionVectors": [
      "Contaminated medical equipment and solutions",
      "Hands of healthcare workers",
      "Person-to-person transmission in hospital settings"
    ],
    "prognosisNotes": [
      "The prevalence of multi-drug resistant (MDR) strains is increasing, which can complicate treatment and worsen outcomes.",
      "Infections with carbapenemase-producing strains are associated with high mortality rates."
    ]
  },
  "resistanceProfile": {
    "groupIntrinsicResistance": [],
    "intrinsicResistance": [
      {
        "drugOrClass": "Polymyxins (Colistin)",
        "notes": "Chromosomally-mediated resistance."
      },
      {
        "drugOrClass": "Ampicillin",
        "notes": ""
      },
      {
        "drugOrClass": "Ampicillin-sulbactam",
        "notes": ""
      },
      {
        "drugOrClass": "Amoxicillin-clavulanate",
        "notes": ""
      },
      {
        "drugOrClass": "Cefazolin",
        "notes": ""
      },
      {
        "drugOrClass": "Cephamycins (e.g., Cefoxitin, Cefotetan)",
        "notes": ""
      },
      {
        "drugOrClass": "Nitrofurantoin",
        "notes": ""
      }
    ],
    "majorMechanisms": [
      {
        "mechanismName": "AmpC Beta-Lactamase",
        "mechanismType": "Enzymatic Inactivation",
        "description": "Serratia marcescens possesses a chromosomal AmpC beta-lactamase that is typically inducible but can be constitutively overexpressed, conferring resistance to penicillins, early-generation cephalosporins, and cephamycins. Clinical significance of induction is less common than in Enterobacter."
      },
      {
        "mechanismName": "Extended-Spectrum Beta-Lactamases (ESBLs)",
        "mechanismType": "Enzymatic Inactivation",
        "description": "Acquired plasmid-mediated enzymes (e.g., CTX-M, SHV, TEM) that hydrolyze most penicillins and cephalosporins, including 3rd and 4th generation cephalosporins, and aztreonam."
      },
      {
        "mechanismName": "Carbapenemases",
        "mechanismType": "Enzymatic Inactivation",
        "description": "Can acquire genes for serine carbapenemases (e.g., KPC) or metallo-beta-lactamases (e.g., NDM, VIM, IMP), leading to resistance to nearly all beta-lactam agents, including carbapenems."
      },
      {
        "mechanismName": "Aminoglycoside-Modifying Enzymes",
        "mechanismType": "Enzymatic Inactivation",
        "description": "Enzymes that acetylate, phosphorylate, or adenylate aminoglycosides, preventing them from binding to the ribosome."
      }
    ],
    "clinicalAlerts": [
      {
        "alertTitle": "Potential for Multi-Drug Resistance",
        "details": "Serratia marcescens frequently acquires resistance genes, leading to ESBL, AmpC, and carbapenemase production. Susceptibility testing is essential to guide therapy."
      },
      {
        "alertTitle": "AmpC Stability Considerations",
        "details": "For serious infections, cefepime may be preferred over third-generation cephalosporins (e.g., ceftriaxone) due to its greater stability against hydrolysis by AmpC beta-lactamases, particularly in high-inoculum infections."
      }
    ]
  },
  "treatment": {
    "generalNotes": [
      "The following recommendations are for moderately severe or severe infections. For uncomplicated infections, options may include second and third-generation cephalosporins if susceptible.",
      "TMP-SMX is a viable option if the isolate is proven susceptible.",
      "Serratia marcescens is intrinsically resistant to Nitrofurantoin.",
      "Susceptibility to Fosfomycin is variable and requires testing."
    ],
    "drugsToAvoid": [
      {
        "drugOrClass": "Polymyxins (Colistin)",
        "condition": "All infections",
        "reason": "Intrinsic resistance."
      },
      {
        "drugOrClass": "Ampicillin, Amoxicillin-clavulanate, Cefazolin, Cephamycins",
        "condition": "All infections",
        "reason": "Intrinsic resistance."
      }
    ],
    "adjunctiveTherapies": [],
    "regimens": [
      {
        "context": {
          "type": "Empiric",
          "condition": "Suspected Serratia marcescens infection",
          "patientPopulation": [
            "Areas with local resistance rates <10-15% to 3rd-generation cephalosporins"
          ]
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Monotherapy",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Piperacillin-tazobactam",
                    "dose": "4.5 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "infused over 4 hr"
                  },
                  {
                    "drugName": "Cefepime",
                    "dose": "1-2 gm",
                    "route": "IV",
                    "frequency": "q8h-q12h",
                    "comments": ""
                  },
                  {
                    "drugName": "Ceftriaxone",
                    "dose": "1-2 gm",
                    "route": "IV",
                    "frequency": "q24h",
                    "comments": ""
                  },
                  {
                    "drugName": "Aztreonam",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": ""
                  },
                  {
                    "drugName": "Ciprofloxacin",
                    "dose": "400 mg",
                    "route": "IV",
                    "frequency": "q12h",
                    "comments": ""
                  },
                  {
                    "drugName": "Levofloxacin",
                    "dose": "750 mg",
                    "route": "IV",
                    "frequency": "once daily",
                    "comments": ""
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "context": {
          "type": "Empiric",
          "condition": "Suspected Serratia marcescens infection, severe illness",
          "patientPopulation": [
            "Areas with local resistance rates >15% to 3rd-generation cephalosporins",
            "Critically ill patients",
            "Recent antibiotic exposure"
          ]
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Monotherapy",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Meropenem",
                    "dose": "1-2 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": ""
                  },
                  {
                    "drugName": "Ertapenem",
                    "dose": "1 gm",
                    "route": "IV",
                    "frequency": "q24h",
                    "comments": "Not for Pseudomonas coverage if a mixed infection is suspected."
                  }
                ]
              }
            ],
            "notes": ["Reserve carbapenems for mixed infections or for documented ESBL-producing strains."]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "Serratia marcescens infection, susceptible to 3rd-generation cephalosporins",
          "patientPopulation": [
            "All"
          ],
          "isolateSource": "Any"
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Monotherapy",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Ceftriaxone",
                    "dose": "1-2 gm",
                    "route": "IV",
                    "frequency": "once daily",
                    "comments": ""
                  },
                  {
                    "drugName": "Cefepime",
                    "dose": "1-2 gm",
                    "route": "IV",
                    "frequency": "q8h-q12h",
                    "comments": ""
                  },
                   {
                    "drugName": "Piperacillin-tazobactam",
                    "dose": "Dose based on susceptibility report",
                    "route": "IV",
                    "frequency": "",
                    "comments": ""
                  },
                  {
                    "drugName": "Ciprofloxacin",
                    "dose": "400 mg",
                    "route": "IV",
                    "frequency": "q12h",
                    "comments": "If susceptible."
                  },
                  {
                    "drugName": "Levofloxacin",
                    "dose": "750 mg",
                    "route": "IV",
                    "frequency": "once daily",
                    "comments": "If susceptible."
                  },
                  {
                    "drugName": "TMP-SMX",
                    "dose": "8-10 mg/kg/day (TMP component)",
                    "route": "IV",
                    "frequency": "divided q6h",
                    "comments": "If susceptible."
                  }
                ]
              }
            ],
            "notes": [ "IDSA guidance suggests selecting treatment based on AST results. Cefepime may be preferred over Ceftriaxone for high inoculum infections due to its greater stability to AmpC." ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "ESBL and/or AmpC-producing Serratia marcescens infection",
          "patientPopulation": [
            "All"
          ],
          "isolateSource": "Any"
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Monotherapy",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Meropenem",
                    "dose": "1-2 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": ""
                  },
                  {
                    "drugName": "Ertapenem",
                    "dose": "1 gm",
                    "route": "IV",
                    "frequency": "q24h",
                    "comments": "Not for Pseudomonas coverage or CNS infections."
                  }
                ]
              }
            ]
          },
          {
            "preference": "Alternative",
            "strategy": "Monotherapy",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Ciprofloxacin",
                    "dose": "400 mg IV q12h or 750 mg po bid",
                    "route": "IV/PO",
                    "frequency": "q12h/bid",
                    "comments": "Only if susceptible."
                  },
                  {
                    "drugName": "Levofloxacin",
                    "dose": "750 mg",
                    "route": "IV/PO",
                    "frequency": "once daily",
                    "comments": "Only if susceptible."
                  },
                  {
                    "drugName": "TMP-SMX",
                    "dose": "8-10 mg/kg/day (TMP component)",
                    "route": "IV",
                    "frequency": "divided q6h",
                    "comments": "Only if susceptible."
                  },
                  {
                    "drugName": "Ceftolozane-tazobactam",
                    "dose": "1.5 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "infused over 3h; limited clinical data vs Serratia"
                  },
                  {
                    "drugName": "Temocillin",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "q12h",
                    "comments": "Where available"
                  },
                   {
                    "drugName": "Cefepime",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "For mild/moderate infection with controlled source and MIC <=2 mcg/mL."
                  }
                ]
              }
            ],
            "notes": [ "Ceftazidime-avibactam has in vitro activity but limited clinical data for this specific resistance pattern." ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "KPC-producing carbapenem-resistant Serratia marcescens infection",
          "patientPopulation": [
            "All"
          ],
          "isolateSource": "Any"
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Monotherapy",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Ceftazidime-avibactam",
                    "dose": "2.5 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "infused over 3 hrs"
                  },
                  {
                    "drugName": "Meropenem-vaborbactam",
                    "dose": "4 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "infused over 3 hrs"
                  }
                ]
              }
            ],
            "notes": [ "Infectious diseases consultation recommended." ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "Metallo-beta-lactamase (MBL)-producing carbapenem-resistant Serratia marcescens infection",
          "patientPopulation": [
            "All"
          ],
          "isolateSource": "Any"
        },
        "recommendations": [
          {
            "preference": "Primary",
            "strategy": "Concurrent",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Ceftazidime-avibactam",
                    "dose": "2.5 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "infused over 3 hrs"
                  },
                  {
                    "drugName": "Aztreonam",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "q6h",
                    "comments": "infused over 3h"
                  }
                ]
              }
            ],
            "notes": ["Aztreonam is stable to MBLs, while avibactam protects aztreonam from co-produced ESBLs/AmpC."]
          },
          {
            "preference": "Alternative",
            "strategy": "Monotherapy",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Cefiderocol",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "q8h",
                    "comments": "infused over 3 hrs"
                  },
                   {
                    "drugName": "Plazomicin",
                    "dose": "15 mg/kg",
                    "route": "IV",
                    "frequency": "once daily",
                    "comments": "For complicated UTI only, if available."
                  }
                ]
              }
            ],
            "notes": [ "Infectious diseases consultation is essential as there is no proven effective therapy." ]
          }
        ]
      },
      {
        "context": {
          "type": "Directed",
          "condition": "Serratia marcescens infection",
          "patientPopulation": [
            "Severe IgE-mediated beta-lactam allergy"
          ]
        },
        "recommendations": [
          {
            "preference": "Alternative",
            "strategy": "Monotherapy",
            "steps": [
              {
                "step": 1,
                "duration": "Variable",
                "drugs": [
                  {
                    "drugName": "Aztreonam",
                    "dose": "2 gm",
                    "route": "IV",
                    "frequency": "q6h",
                    "comments": "Generally safe, but check for cross-reactivity if allergy is to ceftazidime."
                  },
                  {
                    "drugName": "Ciprofloxacin",
                    "dose": "400 mg IV or 750 mg po",
                    "route": "IV/PO",
                    "frequency": "q12h/bid",
                    "comments": "If susceptible."
                  },
                  {
                    "drugName": "Levofloxacin",
                    "dose": "750 mg",
                    "route": "IV/PO",
                    "frequency": "once daily",
                    "comments": "If susceptible."
                  },
                  {
                    "drugName": "Gentamicin or Tobramycin",
                    "dose": "7 mg/kg loading dose then 5.1 mg/kg",
                    "route": "IV",
                    "frequency": "q24h",
                    "comments": "Therapeutic drug monitoring required."
                  }
                ]
              }
            ]
          }
        ]
      }
    ]
  },
  "laboratoryProfile": {
    "testingIndications": ["Susceptibility testing should be performed on all clinically significant isolates of Serratia marcescens."],
    "methodologyNotes": ["Broth microdilution is the recommended method for susceptibility testing, especially for critical agents like polymyxins. Disk diffusion may be unreliable for some agent/organism combinations."],
    "recommendedPanel": ["Primary panel should include agents from Tier 1 and Tier 2. Tier 3 and 4 agents should be tested based on institutional epidemiology, patient risk factors, or on isolates resistant to primary agents."],
    "specialTests": [
        {
            "testName": "Carbapenemase Production Test (e.g., mCIM, CarbaNP)",
            "trigger": "Resistance to one or more carbapenems (ertapenem, meropenem).",
            "purpose": "To detect the presence of carbapenemase enzymes, which has significant therapeutic and infection control implications."
        },
        {
            "testName": "ESBL Phenotypic Test",
            "trigger": "Elevated MICs to ceftazidime or ceftriaxone, though often performed reflexively.",
            "purpose": "To detect the presence of ESBL enzymes."
        }
    ],
    "reportingRules": [
        {
            "ruleType": "Conditional",
            "drug": "Cefepime",
            "condition": "Isolate demonstrates carbapenemase production.",
            "details": "Cefepime Susceptible/SDD results should be suppressed or edited and reported as Resistant."
        }
    ],
    "antimicrobialBreakpoints": [
      {
        "tier": 1,
        "tierDescription": "Appropriate for routine, primary testing and reporting",
        "agents": [
          {
            "agentName": "Ampicillin",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "10 µg",
                  "s_breakpoint": "≥ 17",
                  "i_breakpoint": "14–16",
                  "r_breakpoint": "≤ 13"
                },
                "mic": {
                  "s_breakpoint": "≤ 8",
                  "i_breakpoint": "16",
                  "r_breakpoint": "≥ 32"
                },
                "comments": [
                  "Results of ampicillin testing can be used to predict results for amoxicillin."
                ]
              }
            ]
          },
          {
            "agentName": "Cefazolin",
            "breakpointSets": [
              {
                "condition": "Urine Only (Uncomplicated UTI)",
                "diskDiffusion": {
                  "diskContent": "30 µg",
                  "s_breakpoint": "≥ 15",
                  "i_breakpoint": "—",
                  "r_breakpoint": "≤ 14"
                },
                "mic": {
                  "s_breakpoint": "≤ 16",
                  "i_breakpoint": "—",
                  "r_breakpoint": "≥ 32"
                },
                "comments": [
                  "Serves as a surrogate for oral cephalosporins for E. coli, K. pneumoniae, and P. mirabilis. Note: Serratia is intrinsically resistant to cefazolin for systemic infections."
                ]
              }
            ]
          },
          {
            "agentName": "Amoxicillin-clavulanate",
            "breakpointSets": [
              {
                "condition": "Uncomplicated UTI only",
                "diskDiffusion": {
                  "diskContent": "20/10 µg",
                  "s_breakpoint": "≥ 18",
                  "i_breakpoint": "—",
                  "r_breakpoint": "≤ 17"
                },
                "mic": {
                  "s_breakpoint": "≤ 8/4",
                  "i_breakpoint": "16/4",
                  "r_breakpoint": "≥ 32/4"
                },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Piperacillin-tazobactam",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "100/10 µg",
                  "s_breakpoint": "≥ 25",
                  "i_breakpoint": "21–24",
                  "r_breakpoint": "≤ 20"
                },
                "mic": {
                  "s_breakpoint": "≤ 8/4",
                  "i_breakpoint": "16/4",
                  "r_breakpoint": "≥ 32/4"
                },
                "comments": []
              }
            ]
          }
        ]
      },
      {
        "tier": 2,
        "tierDescription": "Appropriate for routine, primary testing, may be reported following cascade reporting rules",
        "agents": [
          {
            "agentName": "Cefepime",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "30 µg",
                  "s_breakpoint": "≥ 25",
                  "i_breakpoint": "19–24",
                  "r_breakpoint": "≤ 18"
                },
                "mic": {
                  "s_breakpoint": "≤ 4",
                  "i_breakpoint": "8",
                  "r_breakpoint": "≥ 16"
                },
                "comments": [
                  "Cefepime S/SDD results should be suppressed or edited and reported as resistant for isolates that demonstrate carbapenemase production."
                ]
              }
            ]
          },
          {
            "agentName": "Ertapenem",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "10 µg",
                  "s_breakpoint": "≥ 22",
                  "i_breakpoint": "19–21",
                  "r_breakpoint": "≤ 18"
                },
                "mic": {
                  "s_breakpoint": "≤ 0.5",
                  "i_breakpoint": "1",
                  "r_breakpoint": "≥ 2"
                },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Meropenem",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "10 µg",
                  "s_breakpoint": "≥ 23",
                  "i_breakpoint": "20–22",
                  "r_breakpoint": "≤ 19"
                },
                "mic": {
                  "s_breakpoint": "≤ 1",
                  "i_breakpoint": "2",
                  "r_breakpoint": "≥ 4"
                },
                "comments": []
              }
            ]
          }
        ]
      },
      {
        "tier": 3,
        "tierDescription": "Appropriate for high-risk MDRO patients, subject to cascade reporting",
        "agents": [
          {
            "agentName": "Ceftazidime-avibactam",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "30/20 µg",
                  "s_breakpoint": "≥ 21",
                  "i_breakpoint": "—",
                  "r_breakpoint": "≤ 20"
                },
                "mic": {
                  "s_breakpoint": "≤ 8/4",
                  "i_breakpoint": "—",
                  "r_breakpoint": "≥ 16/4"
                },
                "comments": [
                  "Confirmatory MIC testing is indicated for isolates with zones of 20–22 mm."
                ]
              }
            ]
          },
          {
            "agentName": "Meropenem-vaborbactam",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "20/10 µg",
                  "s_breakpoint": "≥ 18",
                  "i_breakpoint": "15–17",
                  "r_breakpoint": "≤ 14"
                },
                "mic": {
                  "s_breakpoint": "≤ 4/8",
                  "i_breakpoint": "8/8",
                  "r_breakpoint": "≥ 16/8"
                },
                "comments": [
                  "If an OXA-48-like gene or enzyme is detected, suppress or report as resistant."
                ]
              }
            ]
          }
        ]
      },
      {
        "tier": 4,
        "tierDescription": "May warrant testing and reporting by clinician request if optimal agents in other tiers are not available",
        "agents": [
          {
            "agentName": "Aztreonam",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "30 µg",
                  "s_breakpoint": "≥ 21",
                  "i_breakpoint": "18–20",
                  "r_breakpoint": "≤ 17"
                },
                "mic": {
                  "s_breakpoint": "≤ 4",
                  "i_breakpoint": "8",
                  "r_breakpoint": "≥ 16"
                },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Ceftriaxone",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": {
                  "diskContent": "30 µg",
                  "s_breakpoint": "≥ 26",
                  "i_breakpoint": "20–22",
                  "r_breakpoint": "≤ 19"
                },
                "mic": {
                  "s_breakpoint": "≤ 1",
                  "i_breakpoint": "2",
                  "r_breakpoint": "≥ 4"
                },
                "comments": []
              }
            ]
          },
          {
            "agentName": "Colistin or Polymyxin B",
            "breakpointSets": [
              {
                "condition": "Standard",
                "diskDiffusion": null,
                "mic": {
                  "s_breakpoint": "≤ 2",
                  "i_breakpoint": "—",
                  "r_breakpoint": "≥ 4"
                },
                "comments": [
                  "Disk diffusion and gradient diffusion methods should not be performed.",
                  "Serratia is intrinsically resistant to polymyxins; testing is generally not indicated."
                ]
              }
            ]
          }
        ]
      }
    ]
  },
  "additionalInformation": {
    "diagnosticNotes": {
      "summary": "Identification is typically performed using automated systems (e.g., VITEK, MicroScan) or MALDI-TOF MS. Conventional biochemical tests confirm identity. The ability to produce red pigment (prodigiosin) is a classic but variable characteristic. Non-pigmented strains are common in clinical settings.",
      "biosafetyWarning": "BSL-2: Serratia marcescens is a Biosafety Level 2 organism. Standard laboratory precautions should be followed.",
      "methods": [
        {
          "methodName": "Culture",
          "details": "Grows well on standard laboratory media like Blood Agar and MacConkey Agar. Colonies are non-lactose fermenting (or slow) and may show red pigmentation, especially after incubation at room temperature (22-25°C)."
        },
        {
          "methodName": "MALDI-TOF Mass Spectrometry",
          "details": "Provides rapid and accurate identification to the species level."
        }
      ]
    },
    "preventionAndScreening": [
      {
        "type": "Infection Control",
        "details": "Strict adherence to hand hygiene is paramount. Contact precautions are recommended for patients colonized or infected with MDR strains. Environmental cleaning and disinfection are crucial to prevent outbreaks.",
        "targetPopulation": "Healthcare facilities, especially ICUs and NICUs"
      }
    ],
    "treatmentLifecycle": [],
    "antimicrobialStewardship": [
      "Reserve carbapenems for documented mixed infections or for infections due to confirmed ESBL-producing strains to limit selective pressure for carbapenem resistance.",
      "Reserve Meropenem-vaborbactam and Ceftazidime-avibactam for documented KPC-producing CRE infections.",
      "Avoid using polymyxins (colistin) due to intrinsic resistance."
    ],
    "drugSpecificPearls": [
      {
        "drugName": "Aztreonam + Ceftazidime-avibactam",
        "pearl": "This combination is a key strategy for MBL-producing CRE. Aztreonam is not hydrolyzed by metallo-carbapenemases but is inactivated by co-produced ESBLs and AmpC; avibactam protects aztreonam by inhibiting these other beta-lactamases."
      },
      {
        "drugName": "Cefiderocol",
        "pearl": "A siderophore cephalosporin used as a last-line agent for CRE. In a trial of severely ill patients with carbapenem-resistant infections, all-cause mortality was numerically higher in the cefiderocol arm compared to the best available therapy arm (24.8% vs 18.4%), although this was not statistically significant. Use should be reserved for patients with limited or no other treatment options."
      }
    ],
    "guidelineReferences": [
      {
        "source": "IDSA",
        "citation": "Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections (2024 Update or latest version)",
        "summaryOrNote": "Provides evidence-based recommendations for the management of infections caused by ESBL-producing, AmpC-producing, and carbapenem-resistant Enterobacterales."
      }
    ]
  }
}
